Melatonin in Patients With Multiple Sclerosis (MS).
Active, not recruiting
Providence Health & Services
Early Phase 1
2018-05-09
To date, there are no published data on the role of melatonin supplementation or the
appropriate dose for patients with multiple sclerosis. Because of the potential benefits of
melatonin, this pilot study will be an exploratory investigation to evaluate the effect of
supplementing melatonin in subjects with multiple sclerosis who are taking an oral disease
modifying therapy (DMT) for 6 months or longer. It is our intent that the results of this
study will support the rationale and be a prelude to a larger trial which can focus on
clinical efficacy of melatonin therapy outcomes.
A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)
Not yet recruiting
Biogen
Phase 3
2021-11-19
The primary objectives of this study are to determine the safety and tolerability of DRF
administered for up to 24 weeks in adult East Asian participants with RMS (Part 1) and to
determine the safety and tolerability of DRF administered for up to 48 weeks in adult East
Asian participants with RMS (Part 2).
The secondary objective of this study is to evaluate the pharmacokinetic(s) (PK) of DRF
metabolites (monomethyl fumarate [MMF] and 2-hydroxyethyl succinimide [HES]) following
multiple doses of DRF in a subset of adult East Asian participants with RMS (Part 1).
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (DRF) in Chinese and Caucasian Adult Healthy Participants
Not yet recruiting
Biogen
Phase 1
2022-01-31
The primary objective is to evaluate the primary pharmacokinetic (PK) parameters of DRF
active metabolite monomethyl fumarate (MMF) following multiple doses of DRF in Chinese and
Caucasian adult healthy participants. The secondary objectives are to evaluate the secondary
PK parameters of DRF active metabolite MMF following multiple doses of DRF in Chinese and
Caucasian adult healthy participants, to evaluate the PK of DRF inactive major metabolite
2-hydroxyethyl succinimide (HES) following multiple doses of DRF in Chinese and Caucasian
adult healthy participants and to evaluate the safety and tolerability of multiple oral doses
of DRF in Chinese and Caucasian adult healthy participants.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
